PIK3CG and neoplasm: IPI549 (eganelisib), a PI3k inhibitor that is specific to the γ isoform (Class I), was developed by Infinity Pharmaceuticals as an anti-tumor therapy aimed at reprogramming myeloid cells and will be discussed in the selected experiments presented later in this manuscript [24].